Co-Dx announces $3.0 million private placement
The offering includes common stock and warrants, priced at $1.821 per unit.
See the latest news and media coverage for Co-Dx. We track all announcements, press releases, and industry mentions in real time, all in one place.
Real-time PCR diagnostic test developer
codiagnostics.comLast updated
In short: Co-Dx expanded its global diagnostic footprint through new Saudi Arabian infrastructure, South Asian trade deals, and Ebola test development.
The offering includes common stock and warrants, priced at $1.821 per unit.
The strategy for Bundibugyo virus is complete, allowing rapid test availability if needed, following WHO and CDC alerts.
Operating loss increased to $9.2 million, driven by R&D spending on clinical studies.
The facility in Sudair Industrial City supports Vision 2030 localization goals and spans 14,400 square feet for diagnostic manufacturing.
Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular...
The company said it is prepared to rapidly deploy a Bundibugyo virus Ebola test if outbreak conditions require expanded diagnostic response capabilities. Key Investor TakeawaysCo-Diagnostics...
Earlier today, Co-Diagnostics released financial results from the first quarter ended March 31, 2026. In addition to diagnostic test developments and...
This announcement represents the latest step in Co-Diagnostics' broader strategy to deploy its platform globally through localized partnerships, including its CoSara joint venture in India...
Track Co-Dx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Co-Dx and other trending companies.